A Phase 2 interventional study of LY3537031 and Placebo in Irritable Bowel Syndrome and Diarrhea, sponsored by Eli Lilly and Company. Recruiting at 89 sites in 10 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-04.
Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 344 studies in Irritable Bowel Syndrome with a site in United States — 45 open to participants now, 49 under way, 3 of them phase 3. Irritable Bowel Syndrome · United States.
Among the 344 studies in Irritable Bowel Syndrome with a site in United States, this one is the 27th largest by planned enrollment of the 287 interventional ones that give a count, is one of 17 that started in 2026, is one of 80 in phase 2, reaches primary completion later than 34 of the 48 other live ones, and was the 335th registered.
1,119 studies on the registry are indexed under Irritable Bowel Syndrome; 209 are open to participants now.
Browse Irritable Bowel Syndrome studies →45 of the 344 studies in Irritable Bowel Syndrome with a site in United States are open now. Recruiting first, the newest first:
Johns Hopkins University · Sites in United States
Ages 18+
Baylor College of Medicine · Sites in United States
Ages 7–12
University of Michigan · Sites in United States
Ages 18–65
Kiwi Health Inc · Sites in United States
Ages 18+ · Healthy volunteers
Eli Lilly and Company · Sites in United States, Belgium, Canada and 5 more countries
Ages 18–75
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 127 Irritable Bowel Syndrome studies recruiting now, 33 (26%) set no upper age limit and 84 (66%) stop at 75 or younger; 19 take children under 18; 29 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
344 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 22 · Phase 2 91 · Phase 3 38 · Phase 4 15
First in 1996; this study’s year is marked. 17 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 531 is above the median of 70 across 896 interventional studies indexed under Irritable Bowel Syndrome.
Median enrollment 61 across the 287 interventional studies, 150 across the 55 observational. Of the 274 that completed or were terminated, 104 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
119 of 344 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
Eli Lilly and Company has 2 studies filed under Irritable Bowel Syndrome — fewer than ten, so there is no comparison to draw.
24 of the studies in Irritable Bowel Syndrome with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05519683Phase 3University of MichiganHome Transcutaneous Electrical Acustimulation (TEA) | 2027-03 |
| NCT04506593Indiana UniversityIndiana University Gastrointestinal Motility Diagnosis Registry | 2026-11 |
| NCT06760533NYU Langone HealthPsilocybin-Assisted Psychotherapy in Treating Irritable Bowel Syndrome (IBS) | 2026-12 |
| NCT06288672IBS-80, LLCIBS Skin Patch Test Food Allergy Study | 2026-12 |
| NCT06684470Mayo ClinicNovel Pilot Study to Treat Symptoms of IBS With Diarrhea Using Combination Therapy of a Low-FODMAP Diet and a Neuromodulator | 2026-12-19 |
Add all 24 to your calendar (.ics) → With an account.
Among the 344 studies in Irritable Bowel Syndrome with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate how well brenipatide (LY3537031) is tolerated, what side effects may occur, and the safety and efficacy in participants with Irritable Bowel Syndrome-Diarrhea (IBS-D). The study drug will be administered subcutaneously (SC) (under the skin) when compared with placebo.
The study will last approximately 36 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Based on the daily eDiary collection during the screening period:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LY3537031 administered subcutaneously (SC)
Drug: LY3537031
Placebo administered SC
Drug: Placebo
Administered SC
Also known as: Brenipatide
Administered SC
Percentage of Participants Who Had a Daily Composite Response for at Least 50 Percent (%) of Days
Time frame: Week 9 to Week 16
Percentage of Participants Who Had a Daily Abdominal Pain Response for at Least 50% of Days
Time frame: Week 9 to Week 16
Percentage of Participants Who Had Daily Stool Consistency Response for at Least 50% of Days
Time frame: Week 1 to Week 24
Percentage of Participants Who Had a Daily Composite Response
Time frame: Day 1 through Week 24
Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data are available 6 months after the primary publication or approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting.
Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Data sharing details ↗ · vivli.org
Started May 2026 (actual). Primary completion is estimated for Sep 2027, 16 months after the start.
Of 24 industry-sponsored phase 2 interventional studies under Irritable Bowel Syndrome, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 23. This study's planned 16 months is below that.
Counting every sponsor, half of 42 studies reached it within 21 months; a quarter within 14 and three quarters within 39.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Brenipatide